HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Whey Recall Grows, But Plainview Approach May Prevent A Peanut Replay

This article was originally published in The Tan Sheet

Executive Summary

The recall of whey protein ingredients rippling its way through the dietary supplement industry shows that companies must take a risk-based approach to product safety and cannot rely on good manufacturing practices alone to protect them

You may also be interested in...



Recall Strategy Crucial As Broader Awareness Leaves Firms Vulnerable

As consumer awareness and media attention to food and drug recalls grow, so does the threat recalls pose to firms' bottom lines and the need for companies to build their reputations before problems happen and communicate effectively with the public

Plainview whey recalls continue

Additional firms recall whey protein supplements potentially contaminated with salmonella from Plainview Milk Products Cooperative, including certain batches of SNI Pro Whey from Nutrition Global and Weigh Down Chocolate Flavor Nutrition Drink Mix from Lewis Laboratories International. A spokeswoman for GNC said in an e-mail the retailer's private label whey products are unaffected, but firms recalled four third-party stock-keeping units carried in the stores. Despite the range of firms and products affected by the recalls, Plainview acted quickly and no illnesses are reported linked to its ingredients (1"The Tan Sheet" July 13, 2009)

Peanut Butter Firm’s GMP “Deviation” Offers Lessons For Manufacturers

Shipping product once found to be contaminated, but later rated as safe in tests by a second source is not a good manufacturing practice, according to FDA

Related Content

Topics

UsernamePublicRestriction

Register

RS136377

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel